<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633864</url>
  </required_header>
  <id_info>
    <org_study_id>FMT for IgAN</org_study_id>
    <nct_id>NCT03633864</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for Refractory IgA Nephropathy</brief_title>
  <official_title>Fecal Microbiota Transplantation for Refractory IgA Nephropathy: a Prospective, Single-center, Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IgA nephropathy (IgAN) is one of the most common glomerular diseases worldwide. Current
      treatments for IgAN are limited by their relatively insufficient efficacy and severe adverse
      events. Previous studies suggested that the disorder of intestinal flora may play an
      important role in the pathogenesis and prognosis of IgAN. Fecal microbiota transplantation
      (FMT) have been proved to be effective on rebuilding the intestinal microecological balance.
      However, there is no evidence for the safety and efficacy of FMT in IgAN. Therefore,
      investigators perform a prospective cohort study to evaluate the safety and efficacy of FMT
      in IgAN patients who did not response to the conventional treatment and did not want to
      aggravate immunosuppressive treatments or IgAN patients who did not response to
      immunosuppressive treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Urinary protein</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>24 hours urinary protein quantity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Serum creatinine</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>Concentration of serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of eGFR</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematuria</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>Hematuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Blood pressure</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum IgA1</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>Serum IgA1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Fecal microbiota</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>Fecal microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with FMT</measure>
    <time_frame>one time per week up to 8 weeks</time_frame>
    <description>Adverse events associated with FMT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>FMT treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal microbiota transplantation</intervention_name>
    <description>Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.</description>
    <arm_group_label>FMT treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, age: 18-65 years old.

          -  Pathological diagnosis with IgAN, eGFR：20-120 mL/min/1.73 m2.

          -  The 24-hour urinary protein was still greater than 1g after 3-6 months of treatment of
             ACEI/ARB

          -  Recurrence of IgAN after glucocorticoid and (or)immunosuppressant decrement and the
             24-hour urinary protein was greater than 1g.

          -  Not suitable for the administration of glucocorticoid and (or) immunosuppressive
             agents because of side effects.

          -  Women of child-bearing age with negative urine pregnancy test have no pregnancy plan
             for the next 18 months and take effective contraceptive measures.

          -  Agree to participate in this clinical trial

        Exclusion Criteria:

          -  Malignant tumors and other diseases with expected survival time &lt;3 months.

          -  Severe cardiovascular and cerebrovascular diseases and pulmonary dysfunction.

          -  Other immune system diseases.

          -  Diabetes

          -  Inflammatory bowel disease（IBD）

          -  Clostridium difficile infection

          -  Gastrointestinal tumor

          -  Active gastrointestinal bleeding

          -  Acute and chronic gastroenteritis

          -  Have received or are receiving FMT treatment.

          -  HIV

          -  Psychosis AND dysgnosia

          -  Contraindication of colonoscopy and enema

          -  Alcohol/drug abuse

          -  Other conditions that the researchers thought were not appropriate for the group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiren Sun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital, the Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiren Sun, M.D.</last_name>
    <phone>+8602984775193</phone>
    <email>sunshiren@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Bai, M.D</last_name>
    <phone>+8602984775193</phone>
    <email>mingbai1983@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of Nephrology</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiren Sun, M.D.</last_name>
      <phone>+8602984775193</phone>
      <email>sunshiren@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ming Bai, M.D.</last_name>
      <phone>+8602984775193</phone>
      <email>mingbai1983@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shiren Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 18, 2018</last_update_submitted>
  <last_update_submitted_qc>August 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Shiren sun</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>IgA nephropathy</keyword>
  <keyword>fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

